BiotechTube

VK2809 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia, NAFLD

Trial Timeline

Sep 28, 2016 → Mar 26, 2019

NCT ID
NCT02927184

About VK2809 + Placebo

VK2809 + Placebo is a phase 2 stage product being developed by Viking Therapeutics for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02927184. Target conditions include Hyperlipidemia, NAFLD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02927184Phase 2Completed

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
77
Diet+pravastatinDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
85
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
77
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
77
exenatideEli LillyPre-clinical
23
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
33
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
33
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
41
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
52
Rosuvastatin (Crestor)AstraZenecaApproved
85
simvastatin + EzetimibeMerckApproved
85
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
77
simvastatin 20 mg/ezetimibeMerckPhase 2/3
65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
77
Sitagliptin + PlaceboMerckPhase 2/3
65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)NovartisPhase 1
33

Other Products from Viking Therapeutics

VK2735Phase 3
72
VK2735Phase 3
72
Placebo + VK2735Phase 2
47
VK2735 + PlaceboPhase 2
47
VK5211 + PlaceboPhase 2
47